EQIX
No clear edge
Oct 29, 2026
· Equinix, Inc.
· evidence 7/10
Mostly right — but half is re-rating.
EQIX's Q3 2026 print (Oct 28) confirmed exceptional AI/interconnection demand — record $533M bookings (+35% YoY), MRR +11% cc, third consecutive guidance raise. The +4.8% idiosyncratic move is fundamentally justified in direction, but the guidance raise was only ~2% of AFFO and ~$31M of it came from the inorganic atNorth deal, so the incremental news does not cover a +4.8%…
Entry $1,007.66 (2026-10-28)
Outcome pending
BAC
Lean bullish
Oct 29, 2026
· Bank of America Corporation
· edge 5.5/10· evidence 7.5/10
Mostly — but overdone.
BAC's selloff is directionally understandable but probably excessive relative to the evidence. The stock has been derated for a finalized regulatory penalty, weak investment-banking and FICC revenue, and an unquantified compliance-remediation tail. Yet the operating bank still produced 8% NII growth, 7% loan growth, 2% deposit growth, and contained credit costs in Q3. If Q4…
Entry $50.85 (2026-10-28)
Outcome pending
HYPE
Lean bearish
Oct 29, 2026
· edge 5/10· evidence 8/10
Mostly no — narrative premium.
HYPE's 13.7% pop is idiosyncratic narrative repricing on a misattributed volume headline (SPCX perp volume is mostly Binance's, not Hyperliquid's) triggered by an unconfirmed SpaceX IPO rumor. Hyperliquid's fundamentals are genuinely strong — ~$834M annualized perp revenue with ~99% routed to Assistance Fund HYPE buybacks (~$826M/yr ≈ 3.8% of mcap) — but SPCX adds at most…
Entry $90.81 (2026-10-29)
Outcome pending